



Report Details

Creation Date: 2/2/2026
Created By: SY
Reviewed Date:


Physician: Bleszynski, Peter A
Hospital:
City:

Patient Information

Name: MTV RicFra 31786581
Sex: Male
Year Of Birth (Age): 1943 (82)
Height: 1.72 m
Weight: 70 kg
BMI: 23.66 kg/m²
BSA: 1.83 m²

Comments: Any virtual valve shown is for illustration only. Great quality scan. Annulus in the range for a 26 mm S3U with ~18% OS. Sinuses are > 31 with STJ 31 mm in diameter. Coronary heights are 8.9 and 14.5 left and right, respectively. LM is lower but the VTC is >3 mm and is a low risk for coronary occlusion. Deployment of 80/20 could also be recommended. Valve appears tri-leaflet with moderately heavy leaflet calcifications with 51 degree aortic root angle. TF is sufficient caliber bilaterally for 14 Fr Esheath.

Aortic Valve Graphic



Comments:

Aortic Valve Table


Annulus Area	438.1 mm ²
Annulus Area Derived Ø	23.6 mm
LVOT Area	426.8 mm ²
LVOT Area Derived Ø	23.3 mm
Sinus of Valsalva Width - Left	33.6 mm
Sinus of Valsalva Width - Right	31.5 mm
Sinus of Valsalva Width - Non	33.9 mm

LCA Height	8.9 mm
RCA Height	14.5 mm
STJ Height	20.9 mm
STJ Ø - Avg	31.2 mm
Coplanar View	LAO 2 ° CAU 20 °
Aortic Annulus Angle	51 °


Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.


26 mm VV to RCA at 80/20




26 mm VV to LM at 80/20



Annulus 30%






LVOT 30%







Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.







Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.





Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.



Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.




Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.

Dimmed background

RAO: 38°
Caudal: 0°




Dimmed background

LAO: 46°
Caudal: 0°



Angio Right




Angio Left



Case Report



Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.

RAO: 0°
Caudal: 0°




Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.

**Case Report**

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.

**Case Report**

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.

Edwards SAPIEN 3 Platform

Focus on the Outcomes That Matter

Predictors of 1 year Mortality	Hazard Ratio (95% CI)
Major Stroke ¹	5.38
Moderate-Severe PVL ¹	1.88
Permanent Pacemaker Implantation ²	1.31

Predictors of 1 year Mortality	Hazard Ratio (95% CI)
Severe patient- prosthesis mismatch ³	1.19
Moderate patient- prosthesis mismatch ³	1.0

Edwards SAPIEN 3 Platform Patient Prosthesis Mismatch Tables According to VARC 3 Guidelines⁴ BMI < 30kg/m²

Calculated by mean EOA reference data, by valve size

Indexed EOA by Valve Size, TVT Registry Data

THV Size		20 mm	23 mm	26 mm	29 mm
EOA, cm ²		1.40 ± 0.43	1.60 ± 0.47	1.90 ± 0.53	2.10 ± 0.60
Patient BSA (m ²)	1.5	0.93	1.07	1.27	1.40
	1.6	0.88	1.00	1.19	1.31
	1.7	0.82	0.94	1.12	1.24
	1.8	0.78	0.89	1.06	1.17
	1.9	0.74	0.84	1.00	1.11
	2	0.70	0.80	0.95	1.05
	2.1	0.67	0.76	0.90	1.00
	2.2	0.64	0.73	0.86	0.95
	2.3	0.61	0.70	0.83	0.91
	2.4	0.58	0.67	0.79	0.88
	2.5	0.56	0.64	0.76	0.84
	2.6	0.54	0.62	0.73	0.81
	2.7	0.52	0.59	0.70	0.78
	2.8	0.50	0.57	0.68	0.75

Indexed EOA, Bench Testing at 25 Years of Simulated Wear

THV Size		20 mm	23 mm	26 mm	29 mm
EOA, cm ²		1.56 ± 0.01	1.97 ± 0.01	2.45 ± 0.03	2.70 ± 0.01
Patient BSA (m ²)	1.5	1.04	1.31	1.63	1.80
	1.6	0.98	1.23	1.53	1.69
	1.7	0.92	1.16	1.44	1.59
	1.8	0.87	1.09	1.36	1.50
	1.9	0.82	1.04	1.29	1.42
	2	0.78	0.99	1.23	1.35
	2.1	0.74	0.94	1.17	1.29
	2.2	0.71	0.90	1.11	1.23
	2.3	0.68	0.86	1.07	1.17
	2.4	0.65	0.82	1.02	1.13
	2.5	0.62	0.79	0.98	1.08
	2.6	0.60	0.76	0.94	1.04
	2.7	0.58	0.73	0.91	1.00
2.8	0.56	0.70	0.88	0.96	

Sathananthan J, Hensley M, Landes U, et al. Long-term durability of transcatheter heart valves insights from bench testing to 25 Years. JACC: Cardiovascular Imaging. Published online Sept 28, 2019.

Edwards SAPIEN 3 Platform Patient Prosthesis Mismatch Tables for Patients According to VARC 3 Guidelines⁴ BMI ≥ 30kg/m²

Calculated by mean EOA reference data, by valve size

Indexed EOA by Valve Size, TVT Registry Data

THV Size		20 mm	23 mm	26 mm	29 mm
EOA, cm ²		1.40 ± 0.43	1.60 ± 0.47	1.90 ± 0.53	2.10 ± 0.60
Patient BSA (m ²)	1.5	0.93	1.07	1.27	1.40
	1.6	0.88	1.00	1.19	1.31
	1.7	0.82	0.94	1.12	1.24
	1.8	0.78	0.89	1.06	1.17
	1.9	0.74	0.84	1.00	1.11
	2	0.70	0.80	0.95	1.05
	2.1	0.67	0.76	0.90	1.00
	2.2	0.64	0.73	0.86	0.95
	2.3	0.61	0.70	0.83	0.91
	2.4	0.58	0.67	0.79	0.88
	2.5	0.56	0.64	0.76	0.84
	2.6	0.54	0.62	0.73	0.81
	2.7	0.52	0.59	0.70	0.78
	2.8	0.50	0.57	0.68	0.75

Indexed EOA, Bench Testing at 25 Years of Simulated Wear

THV Size		20 mm	23 mm	26 mm	29 mm
EOA, cm ²		1.56 ± 0.01	1.97 ± 0.01	2.45 ± 0.03	2.70 ± 0.01
Patient BSA (m ²)	1.5	1.04	1.31	1.63	1.80
	1.6	0.98	1.23	1.53	1.69
	1.7	0.92	1.16	1.44	1.59
	1.8	0.87	1.09	1.36	1.50
	1.9	0.82	1.04	1.29	1.42
	2	0.78	0.99	1.23	1.35
	2.1	0.74	0.94	1.17	1.29
	2.2	0.71	0.90	1.11	1.23
	2.3	0.68	0.86	1.07	1.17
	2.4	0.65	0.82	1.02	1.13
	2.5	0.62	0.79	0.98	1.08
	2.6	0.60	0.76	0.94	1.04
	2.7	0.58	0.73	0.91	1.00
2.8	0.56	0.70	0.88	0.96	

Sathananthan J, Hensley M, Landes U, et al. Long-term durability of transcatheter heart valves insights from bench testing to 25 Years. JACC: Cardiovascular Imaging. Published online Sept 28, 2019.

- Arnold SV, et al. Impact of short-term complications on mortality and quality of life after transcatheter aortic valve replacement. JACC 2019; 12(4):362-369.
- Fadahuni OO, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement – Analysis from the U.S. STS/ACC TVT Registry. JACC: Cardio Inter 2016;9(21):2189-2199.
- Herrmann HC, et al. Prosthesis-patient mismatch in 62,125 patients following transcatheter aortic valve replacement – from the STS/ACC TVT Registry. DOI: 10.1016/j.jacc.2018.09.001.
- Généreux P, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research, European Heart Journal 2021; 00: 1-33. doi:10.1093/eurheartj/ehaa799.

See accompanying Important Safety Information.

CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN 3 and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2024 Edwards Lifesciences Corporation. All rights reserved. PP-US-4776 v2.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com




Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.

Edwards SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA Heart Valve System

Annulus Sizing And Vascular Access

Complete Range of Valve Sizes Expands the Treatable Patient Population



SAPIEN 3 Ultra RESILIA valve shown

	20 mm	23 mm	26 mm	29 mm
Inflation Volume	11 mL	17 mL	23 mL	33 mL
Valve Nominal Areas (CT)	328 mm ²	406 mm ²	519 mm ²	649 mm ²
Area (CT)	273 - 345 mm ²	338 - 430 mm ²	430 - 546 mm ²	540 - 683 mm ²
Area-derived Diameter (CT)	18.6 - 21.0 mm	20.7 - 23.4 mm	23.4 - 26.4 mm	26.2 - 29.5 mm
Crimped Height*	21 mm	24.5 mm	27 mm	31 mm
Expanded Height	15.5 mm	18 mm	20 mm	22.5 mm
Foreshortening	5.5 mm	6.5 mm	7 mm	8.5 mm
Inner Skirt Height†	7.9 mm	9.3 mm	10.2 mm	11.6 mm
Outer Skirt Height - SAPIEN 3 Valve	5.2 mm	6.6 mm	7.0 mm	8.1 mm
Outer Skirt Height - SAPIEN 3 Ultra Valve	7.3 mm	9.0 mm	9.7 mm	NA
Outer Skirt Height - SAPIEN 3 Ultra RESILIA Valve	7.3 mm	9.0 mm	9.7 mm	11.0 mm

Transcatheter heart valve size recommendations are based on native valve annulus size, as measured by transesophageal echocardiography (TEE) or computed tomography (CT). Patient anatomical factors and multiple imaging modalities should be considered during the transcatheter heart valve size selection. Risks associated with undersizing and oversizing should be carefully considered.

Edwards eSheath+ Introducer Set



Access Vessel Sizing	20 mm	23 mm	26 mm	29 mm
Edwards eSheath+ Introducer Set	14F (4.6 mm)	14F (4.6 mm)	14F (4.6 mm)	16F (5.3 mm)
Minimum Vessel Diameter	5.5 mm	5.5 mm	5.5 mm	6 mm
Working Length	36 cm	36 cm	36 cm	36 cm

*Rounded to the nearest 0.5 mm

†Measured at bottom of zig-zag

See accompanying Important Safety Information.

CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards eSheath, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, eSheath, eSheath+, INSPIRIS, INSPIRIS RESILIA, PARTNER, PARTNER 3, RESILIA, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2024 Edwards Lifesciences Corporation. All rights reserved. PP-US-0052 v7.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com



Case Report

Note: The intended use of this report is to provide an adjunctive case planning resource and should not be used for diagnostic purposes.